Antiatherogenic effects of the antioxidant BO-653 in three different animal models
| Autor: | Etsuo Niki, Tatsuhiko Kodama, Akira Hayasaka, Yoshiki Kawabe, M. Nakamura, Yasuhiro Ohba, Hiroshi Kaise, Atsuko Higashida, Kunio Tamura, Hisashi Sakaguchi, Tsukasa Suzuki, Yoshiaki Takashima, Noriko Noguchi, Yoshiaki Kato, Kenji Inoue, Osamu Cynshi, Motohiro Takeya, Kiyoshi Takahashi |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Male
Antioxidant Arteriosclerosis medicine.medical_treatment Drug Evaluation Preclinical Probucol In Vitro Techniques Pharmacology Antioxidants Mice chemistry.chemical_compound High-density lipoprotein In vivo medicine Animals Potency Benzofurans Mice Knockout Mice Inbred ICR Multidisciplinary Biological Sciences medicine.disease Dietary Fats Lipoproteins LDL Mice Inbred C57BL Disease Models Animal Receptors LDL chemistry Biochemistry Low-density lipoprotein Lipophilicity Female Rabbits Lipoproteins HDL Oxidation-Reduction medicine.drug |
| Zdroj: | Proceedings of the National Academy of Sciences. 95:10123-10128 |
| ISSN: | 1091-6490 0027-8424 |
| Popis: | Antioxidants have been proposed to have antiatherogenic potential by their inhibition of low density lipoprotein (LDL) oxidation. Here, we report an antioxidant, BO-653 (2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di- tert- butylbenzofuran), designed to exhibit antioxidative potency comparable to that of α-tocopherol, but yet possess a high degree of lipophilicity comparable to that of probucol. BO-653 exhibits a high affinity for LDL and is well distributed in aortic vessels in vivo . In atherosclerosis models of rabbits and mice, BO-653 has been shown to be able to suppress the formation of atherosclerotic lesions without untoward side effects. Specifically, there was no reduction of high density lipoprotein levels. This antioxidant provides additional evidence in support of the oxidized-LDL hypothesis, and itself is a promising candidate antioxidant for clinical use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|